Developer docs
API playgroundTry for free, no card

Search company profiles

Neurocode

Full company profile

uuid00hg1h9

Namestring
Neurocode
Legal namestring
Neurocode USA Inc.
Websiteurl
neurocode.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Neurocode is a CAP-accredited and CLIA-licensed clinical neurodiagnostic laboratory headquartered in Bellingham, Washington, specializing exclusively in diagnostic testing for neurological and neuroimmunological disorders. The company operates a portfolio of more than 30 tests across two principal categories: blood-based and CSF biomarkers for Alzheimer's and other neurodegenerative diseases (including p-Tau 217 via the ALZpath Dx assay on Quanterix's Simoa platform, GFAP, NfL, and Aβ42/40), and cell-based and radioimmunoprecipitation assays for neuroimmunological conditions such as myasthenia gravis, NMOSD, MOGAD, CIDP, and LEMS (including AChR, MuSK, LRP4, AQP4, and MOG antibody tests). Neurocode holds an exclusive North American license from Oxford University for the live cell-based assay for AChR antibodies — the only such test in the U.S. — and its p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients, with results published in JAMA Neurology in February 2024.

The company generates revenue on a per-test, pay-as-you-go basis, with all tests requiring a requisition signed by a licensed healthcare provider. Billing is routed to insurance carriers, third-party payors, or patients; pricing is not publicly disclosed, and sample collection kits are provided free of charge. Go-to-market combines enterprise field sales to neurologists and clinicians with direct-to-consumer patient enablement, supported by a national phlebotomy partnership (My One Medical Source) providing 1,500+ blood draw locations across all 50 U.S. states. Neurocode also serves clinical trials and research customers with a customized offering. The company was founded in 2017 (per legal and timeline records) and operates with a small team of PhD scientists, medical laboratory scientists, pathologists, and clinical chemistry specialists. CEO Roopa Reddy leads the firm. Neurocode is privately held, with no disclosed institutional funding, acquisitions, or parent company affiliation.

Short descriptiontext

Neurocode is a CAP-accredited, CLIA-licensed clinical neurodiagnostic laboratory in Bellingham, WA, offering 30+ diagnostic tests for Alzheimer's, myasthenia gravis, and other neurological disorders to neurologists, clinicians, and clinical trial sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBellingham, United States
HQ citystring
Bellingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodiagnostic biomarker testing, Alzheimer's disease diagnostics, neuroimmunology autoantibody testing, clinical laboratory diagnostics, myasthenia gravis testing
Industry2 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Neurological Clinical Diagnostic Laboratory Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Laboratory Diagnostic Testing Services
TypeOne Time License
Description

Neurocode operates as a CAP/CLIA-certified clinical laboratory providing diagnostic tests for neurological disorders. Healthcare providers order tests, and Neurocode processes samples (blood, CSF) and delivers results via a secure web portal. Revenue is generated per test, with sample collection kits provided free of charge. Tests include Alzheimer's biomarkers (p-Tau 217, GFAP, NfL, Aβ42/40), and neuroimmunology assays (AChR, MuSK, LRP4, AQP4, MOG antibodies). All tests must be ordered by a licensed healthcare provider.

neurocode.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Clinical diagnostic testing — no public pricing listed
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing is not publicly disclosed on the website. The company bills insurance and third-party payors. Collection kits are provided free of charge.

neurocode.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1ALZpath Dx
Description

Plasma Phosphorylated Tau 217 (p-Tau 217) test - a breakthrough blood test for Alzheimer's disease diagnosis

neurocode.com
+1 more record
Core offering1 text field

Neurocode is a CAP/CLIA-certified clinical laboratory that runs specialty diagnostic tests for neurological and neuroimmunological disorders. Its portfolio includes blood- and CSF-based biomarkers for Alzheimer's and neurodegenerative disease (p-Tau 217, GFAP, NfL, Aβ42/40 ratio) and cell-based and radioimmunoprecipitation assays for autoantibody-mediated disorders such as myasthenia gravis, NMOSD, MOGAD, and CIDP. Tests are performed on patient samples (blood or CSF) collected through free collection kits and a national phlebotomy partner network, with results delivered to clinicians via a secure web portal.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ALZpath p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients
+2 more records
Product overview1 text field

Neurocode Laboratory is a specialized clinical neurodiagnostic laboratory offering a portfolio of diagnostic tests for neurological disorders. The company provides two main categories of testing: neurodegenerative disease biomarkers including blood-based Alzheimer's tests (p-Tau 217, GFAP, NfL, Aβ42/40) and neuroimmunology tests for myasthenia gravis and related conditions (AChR CBA, AChR RIPA, MuSK RIPA, LRP4 CBA, AQP4 CBA, MOG CBA). Tests use various methodologies including single-molecule array (Simoa), cell-based assays (CBA), radioimmunoprecipitation (RIPA), and chemiluminescence assay (CLEIA). The company operates CAP-accredited and CLIA-certified facilities.

Product and service10 records
1ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217)
CategoryAlzheimer's / neurodegenerative disease biomarker testing
Description

Blood-based biomarker test that measures phosphorylated tau 217 levels using Simoa single-molecule array technology to assist in diagnosis of Alzheimer's disease amyloid pathology; reported AUC=0.932 for identifying amyloid-PET positive patients and validated in JAMA Neurology.

2Acetylcholine Receptor Antibodies by Live Cell-Based Assay (AChR CBA)
CategoryNeuroimmunology autoantibody testing
Description

Live cell-based assay that detects acetylcholine receptor antibodies with maximum sensitivity and specificity to assist in diagnosis of autoimmune myasthenia gravis, including in double-seronegative cases; licensed from Oxford University for exclusive use across North America.

3Acetylcholine Receptor Antibodies by Radioimmunoprecipitation (AChR RIPA)
CategoryNeuroimmunology autoantibody testing
Description

Radioimmunoprecipitation assay that detects acetylcholine receptor antibodies to assist in diagnosis of autoimmune myasthenia gravis.

4Muscle Specific Kinase Antibodies by Radioimmunoprecipitation (MuSK RIPA)
CategoryNeuroimmunology autoantibody testing
Description

Radioimmunoprecipitation assay that detects MuSK antibodies to assist in diagnosis of autoimmune myasthenia gravis.

5Low-Density Lipoprotein Receptor-Related Protein 4 Antibodies by Fixed Cell-Based Assay (LRP4 CBA)
CategoryNeuroimmunology autoantibody testing
Description

Fixed cell-based assay that detects LRP4 antibodies to assist in diagnosis of autoimmune myasthenia gravis.

6Aquaporin-4 Antibodies by Live Cell-Based Assay (AQP4 CBA)
CategoryNeuroimmunology autoantibody testing
Description

Live cell-based assay that detects aquaporin-4 antibodies to assist in diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and to distinguish it from multiple sclerosis.

7Myelin Oligodendrocyte Antibodies by Live Cell-Based Assay (MOG CBA)
CategoryNeuroimmunology autoantibody testing
Description

Live cell-based assay that detects MOG antibodies to assist in diagnosis of myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

8Plasma Glial Fibrillary Acidic Protein (GFAP)
CategoryAlzheimer's / neurodegenerative disease biomarker testing
Description

Blood-based chemiluminescence assay that measures plasma GFAP levels to assist in assessment of neurological disorders.

9Plasma Neurofilament Light Chain (NfL)
CategoryAlzheimer's / neurodegenerative disease biomarker testing
Description

Chemiluminescent enzyme immunoassay that quantifies neurofilament light chain in plasma as a nonspecific biomarker of axonal degeneration associated with neurological disorders including Alzheimer's, ALS, MS, FTD, and TBI.

10CSF Amyloid-Beta 42/40 Ratio (Aβ42/40)
CategoryAlzheimer's / neurodegenerative disease biomarker testing
Description

Cerebrospinal fluid test that measures the amyloid-beta 42/40 ratio as an in vitro diagnostic to assess underlying Alzheimer's disease-associated pathology in conjunction with clinical assessment.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or Integration
Description

Neurocode holds an exclusive license from Oxford University for the live cell-based assay (CBA) for acetylcholine receptor (AChR) antibodies across all of North America. This is the only live CBA for AChR antibodies in the U.S. and provides maximum sensitivity for myasthenia gravis diagnosis — more sensitive than standard RIPA or ELISA methods.

Strategic tierCoreTypeTechnology or Integration
Description

Neurocode offers the ALZpath Dx Plasma Phosphorylated Tau 217 (p-Tau 217) test, a groundbreaking blood test for Alzheimer's diagnosis. ALZpath is the developer of the p-Tau 217 assay, and Neurocode performs the test using in-house Simoa technology.

3Fujirebio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Neurocode conducted a head-to-head comparison study between their ALZpath p-Tau217 assay and Fujirebio's p-Tau217 assay, published as a preprint in Alzheimer's & Dementia (2024). This comparative study validates Neurocode's assay performance against a competitor.

neurocode.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

National phlebotomy partner with over 1,500 convenient locations across all 50 U.S. states. Patients are referred to My One Medical Source for blood draw appointments. Mobile phlebotomy is available for an additional charge. Neurocode includes this partner network as a core component of its patient logistics.

Strategic tierCoreTypeTechnology or Integration
Description

Neurocode's ALZpath p-Tau 217 assay is powered by Simoa (Single Molecule Array) technology from Quanterix. This platform enables ultra-sensitive detection of p-Tau 217 protein at the single-molecule level, achieving AUC=0.932 accuracy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that are increasingly being developed for neurodegenerative biomarkers including p-Tau 217. As a major IVD platform provider, Siemens represents a long-term competitive threat if it launches comparable blood-based Alzheimer's assays at scale.

TypeDirect peer
Description

C2N Diagnostics is the most direct competitor in blood-based Alzheimer's biomarkers with its PrecivityAD test (Aβ42/40 ratio). Both companies are pursuing the same market: replacing PET scans and CSF testing with blood-based assays for amyloid pathology detection. C2N has raised substantial funding and is scaling nationally.

TypeDirect peer
Description

Euroimmun, owned by PerkinElmer, is a leading autoimmune diagnostics company offering cell-based assays for neuroimmunology indications including AChR, MuSK, and AQP4 antibodies. Euroimmun and Neurocode directly compete in neuroimmunology autoantibody testing globally.

TypeOthers
Description

Quanterix develops the Simoa single-molecule array platform that powers Neurocode's p-Tau 217 assay. Quanterix is both a critical technology partner and a potential competitor through its AccuDx direct testing service. Vertical integration risk: if Quanterix brings biomarker testing in-house, Neurocode becomes a customer rather than a service provider.

TypeBroad incumbent
Description

Quest Diagnostics is the largest U.S. clinical reference lab and parent of Athena Diagnostics. Quest competes via national logistics, payor relationships, and routine physician office relationships that are difficult for specialty labs to penetrate. Quest is actively adding Alzheimer's and neuroimmunology blood tests to its menu.

TypeBroad incumbent
Description

Mayo Clinic Laboratories is a major academic reference lab offering extensive neurology and neuroimmunology testing, including cell-based assays and Alzheimer's biomarkers. Mayo has unrivaled brand authority with U.S. neurologists and serves as the default send-out lab for many academic medical centers.

TypeDirect peer
Description

Athena Diagnostics is a Quest subsidiary focused specifically on neurodiagnostic testing, including myasthenia gravis, autoimmune encephalitis, and paraneoplastic panels — directly overlapping Neurocode's neuroimmunology menu. Athena has a much larger sales force and payor footprint but historically lower sensitivity on cell-based assays.

TypeBroad incumbent
Description

ARUP is a national reference laboratory owned by the University of Utah offering extensive neurology, autoimmune, and neuroimmunology testing. ARUP competes with Neurocode in autoantibody testing and serves as a primary reference lab for many U.S. health systems.

TypeBroad incumbent
Description

LabCorp is one of the two largest U.S. clinical reference labs, offering a broad neurology and neuroimmunology menu including MNG Laboratories (acquired 2019). LabCorp competes through scale, payor contracts, and sales force reach that Neurocode cannot match directly.

TypeDirect peer
Description

Fujirebio is the most direct head-to-head competitor for Alzheimer's p-Tau 217 testing via its Lumipulse G pTau 217 assay. Neurocode published a direct comparison study vs. Fujirebio's assay in Alzheimer's & Dementia (2024). Fujirebio has FDA breakthrough designation and a major global installed base of chemiluminescence immunoassay instruments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurocode

Neurological Clinical Diagnostic Laboratory Servicesneurocode.com

Neurocode is a CAP-accredited, CLIA-licensed clinical neurodiagnostic laboratory in Bellingham, WA, offering 30+ diagnostic tests for Alzheimer's, myasthenia gravis, and other neurological disorders to neurologists, clinicians, and clinical trial sponsors.

What Neurocode does

Neurocode is a CAP-accredited and CLIA-licensed clinical neurodiagnostic laboratory headquartered in Bellingham, Washington, specializing exclusively in diagnostic testing for neurological and neuroimmunological disorders. The company operates a portfolio of more than 30 tests across two principal categories: blood-based and CSF biomarkers for Alzheimer's and other neurodegenerative diseases (including p-Tau 217 via the ALZpath Dx assay on Quanterix's Simoa platform, GFAP, NfL, and Aβ42/40), and cell-based and radioimmunoprecipitation assays for neuroimmunological conditions such as myasthenia gravis, NMOSD, MOGAD, CIDP, and LEMS (including AChR, MuSK, LRP4, AQP4, and MOG antibody tests). Neurocode holds an exclusive North American license from Oxford University for the live cell-based assay for AChR antibodies — the only such test in the U.S. — and its p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients, with results published in JAMA Neurology in February 2024.

The company generates revenue on a per-test, pay-as-you-go basis, with all tests requiring a requisition signed by a licensed healthcare provider. Billing is routed to insurance carriers, third-party payors, or patients; pricing is not publicly disclosed, and sample collection kits are provided free of charge. Go-to-market combines enterprise field sales to neurologists and clinicians with direct-to-consumer patient enablement, supported by a national phlebotomy partnership (My One Medical Source) providing 1,500+ blood draw locations across all 50 U.S. states. Neurocode also serves clinical trials and research customers with a customized offering. The company was founded in 2017 (per legal and timeline records) and operates with a small team of PhD scientists, medical laboratory scientists, pathologists, and clinical chemistry specialists. CEO Roopa Reddy leads the firm. Neurocode is privately held, with no disclosed institutional funding, acquisitions, or parent company affiliation.

Neurocode firmographics

Firmographics
Name
Neurocode
Legal name
Neurocode USA Inc.
Website
https://neurocode.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Neurocode is a CAP-accredited, CLIA-licensed clinical neurodiagnostic laboratory in Bellingham, WA, offering 30+ diagnostic tests for Alzheimer's, myasthenia gravis, and other neurological disorders to neurologists, clinicians, and clinical trial sponsors.
Ownership category
akta.pro rank

Neurocode industry classification

Industry
Product category
Neurological Clinical Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Neurodiagnostic biomarker testing
  • Alzheimer's disease diagnostics
  • Neuroimmunology autoantibody testing
  • Clinical laboratory diagnostics
  • Myasthenia gravis testing

Where Neurocode is headquartered

Location

Headquarters

HQ city
Bellingham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neurocode business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Laboratory Diagnostic Testing Services: Neurocode operates as a CAP/CLIA-certified clinical laboratory providing diagnostic tests for neurological disorders. Healthcare providers order tests, and Neurocode processes samples (blood, CSF) and delivers results via a secure web portal. Revenue is generated per test, with sample collection kits provided free of charge. Tests include Alzheimer's biomarkers (p-Tau 217, GFAP, NfL, Aβ42/40), and neuroimmunology assays (AChR, MuSK, LRP4, AQP4, MOG antibodies). All tests must be ordered by a licensed healthcare provider.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goClinical diagnostic testing — no public pricing listed

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Neurocode product offering

Product offering

Core offering

Neurocode is a CAP/CLIA-certified clinical laboratory that runs specialty diagnostic tests for neurological and neuroimmunological disorders. Its portfolio includes blood- and CSF-based biomarkers for Alzheimer's and neurodegenerative disease (p-Tau 217, GFAP, NfL, Aβ42/40 ratio) and cell-based and radioimmunoprecipitation assays for autoantibody-mediated disorders such as myasthenia gravis, NMOSD, MOGAD, and CIDP. Tests are performed on patient samples (blood or CSF) collected through free collection kits and a national phlebotomy partner network, with results delivered to clinicians via a secure web portal.

Product overview

Neurocode Laboratory is a specialized clinical neurodiagnostic laboratory offering a portfolio of diagnostic tests for neurological disorders. The company provides two main categories of testing: neurodegenerative disease biomarkers including blood-based Alzheimer's tests (p-Tau 217, GFAP, NfL, Aβ42/40) and neuroimmunology tests for myasthenia gravis and related conditions (AChR CBA, AChR RIPA, MuSK RIPA, LRP4 CBA, AQP4 CBA, MOG CBA). Tests use various methodologies including single-molecule array (Simoa), cell-based assays (CBA), radioimmunoprecipitation (RIPA), and chemiluminescence assay (CLEIA). The company operates CAP-accredited and CLIA-certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

  • ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217) test - a breakthrough blood test for Alzheimer's disease diagnosis
  • AChR CBA

Products and services

  • ALZpath Dx: Plasma Phosphorylated Tau 217 (p-Tau 217) Blood-based biomarker test that measures phosphorylated tau 217 levels using Simoa single-molecule array technology to assist in diagnosis of Alzheimer's disease amyloid pathology; reported AUC=0.932 for identifying amyloid-PET positive patients and validated in JAMA Neurology.
  • Acetylcholine Receptor Antibodies by Live Cell-Based Assay (AChR CBA) Live cell-based assay that detects acetylcholine receptor antibodies with maximum sensitivity and specificity to assist in diagnosis of autoimmune myasthenia gravis, including in double-seronegative cases; licensed from Oxford University for exclusive use across North America.
  • Acetylcholine Receptor Antibodies by Radioimmunoprecipitation (AChR RIPA) Radioimmunoprecipitation assay that detects acetylcholine receptor antibodies to assist in diagnosis of autoimmune myasthenia gravis.
  • Muscle Specific Kinase Antibodies by Radioimmunoprecipitation (MuSK RIPA) Radioimmunoprecipitation assay that detects MuSK antibodies to assist in diagnosis of autoimmune myasthenia gravis.
  • Low-Density Lipoprotein Receptor-Related Protein 4 Antibodies by Fixed Cell-Based Assay (LRP4 CBA) Fixed cell-based assay that detects LRP4 antibodies to assist in diagnosis of autoimmune myasthenia gravis.
  • Aquaporin-4 Antibodies by Live Cell-Based Assay (AQP4 CBA) Live cell-based assay that detects aquaporin-4 antibodies to assist in diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and to distinguish it from multiple sclerosis.
  • Myelin Oligodendrocyte Antibodies by Live Cell-Based Assay (MOG CBA) Live cell-based assay that detects MOG antibodies to assist in diagnosis of myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
  • Plasma Glial Fibrillary Acidic Protein (GFAP) Blood-based chemiluminescence assay that measures plasma GFAP levels to assist in assessment of neurological disorders.
  • Plasma Neurofilament Light Chain (NfL) Chemiluminescent enzyme immunoassay that quantifies neurofilament light chain in plasma as a nonspecific biomarker of axonal degeneration associated with neurological disorders including Alzheimer's, ALS, MS, FTD, and TBI.
  • CSF Amyloid-Beta 42/40 Ratio (Aβ42/40) Cerebrospinal fluid test that measures the amyloid-beta 42/40 ratio as an in vitro diagnostic to assess underlying Alzheimer's disease-associated pathology in conjunction with clinical assessment.

Quantifiable outcome

  • ALZpath p-Tau 217 assay achieved AUC=0.932 in identifying amyloid-PET positive patients
  • +2 more outcomes

Companies that use Neurocode

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Neurocode technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Neurocode partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Oxford UniversitycoreTechnology or IntegrationNeurocode holds an exclusive license from Oxford University for the live cell-based assay (CBA) for acetylcholine receptor (AChR) antibodies across all of North America. This is the only live CBA for AChR antibodies in the U.S. and provides maximum sensitivity for myasthenia gravis diagnosis — more sensitive than standard RIPA or ELISA methods.
  • ALZpathcoreTechnology or IntegrationNeurocode offers the ALZpath Dx Plasma Phosphorylated Tau 217 (p-Tau 217) test, a groundbreaking blood test for Alzheimer's diagnosis. ALZpath is the developer of the p-Tau 217 assay, and Neurocode performs the test using in-house Simoa technology.
  • FujirebiominorStrategic or Co-development PartnerNeurocode conducted a head-to-head comparison study between their ALZpath p-Tau217 assay and Fujirebio's p-Tau217 assay, published as a preprint in Alzheimer's & Dementia (2024). This comparative study validates Neurocode's assay performance against a competitor.
  • My One Medical SourcecoreChannel Partner/ Reseller/ DistributorNational phlebotomy partner with over 1,500 convenient locations across all 50 U.S. states. Patients are referred to My One Medical Source for blood draw appointments. Mobile phlebotomy is available for an additional charge. Neurocode includes this partner network as a core component of its patient logistics.
  • Simoa (Quanterix)coreTechnology or IntegrationNeurocode's ALZpath p-Tau 217 assay is powered by Simoa (Single Molecule Array) technology from Quanterix. This platform enables ultra-sensitive detection of p-Tau 217 protein at the single-molecule level, achieving AUC=0.932 accuracy.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Neurocode competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that are increasingly being developed for neurodegenerative biomarkers including p-Tau 217. As a major IVD platform provider, Siemens represents a long-term competitive threat if it launches comparable blood-based Alzheimer's assays at scale.
  • Quest Diagnostics: Quest Diagnostics is the largest U.S. clinical reference lab and parent of Athena Diagnostics. Quest competes via national logistics, payor relationships, and routine physician office relationships that are difficult for specialty labs to penetrate. Quest is actively adding Alzheimer's and neuroimmunology blood tests to its menu.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major academic reference lab offering extensive neurology and neuroimmunology testing, including cell-based assays and Alzheimer's biomarkers. Mayo has unrivaled brand authority with U.S. neurologists and serves as the default send-out lab for many academic medical centers.
  • ARUP Laboratories: ARUP is a national reference laboratory owned by the University of Utah offering extensive neurology, autoimmune, and neuroimmunology testing. ARUP competes with Neurocode in autoantibody testing and serves as a primary reference lab for many U.S. health systems.
  • LabCorp: LabCorp is one of the two largest U.S. clinical reference labs, offering a broad neurology and neuroimmunology menu including MNG Laboratories (acquired 2019). LabCorp competes through scale, payor contracts, and sales force reach that Neurocode cannot match directly.

Direct peers

  • C2N Diagnostics: C2N Diagnostics is the most direct competitor in blood-based Alzheimer's biomarkers with its PrecivityAD test (Aβ42/40 ratio). Both companies are pursuing the same market: replacing PET scans and CSF testing with blood-based assays for amyloid pathology detection. C2N has raised substantial funding and is scaling nationally.
  • Euroimmun (PerkinElmer): Euroimmun, owned by PerkinElmer, is a leading autoimmune diagnostics company offering cell-based assays for neuroimmunology indications including AChR, MuSK, and AQP4 antibodies. Euroimmun and Neurocode directly compete in neuroimmunology autoantibody testing globally.
  • Athena Diagnostics (Quest Diagnostics): Athena Diagnostics is a Quest subsidiary focused specifically on neurodiagnostic testing, including myasthenia gravis, autoimmune encephalitis, and paraneoplastic panels — directly overlapping Neurocode's neuroimmunology menu. Athena has a much larger sales force and payor footprint but historically lower sensitivity on cell-based assays.
  • Fujirebio: Fujirebio is the most direct head-to-head competitor for Alzheimer's p-Tau 217 testing via its Lumipulse G pTau 217 assay. Neurocode published a direct comparison study vs. Fujirebio's assay in Alzheimer's & Dementia (2024). Fujirebio has FDA breakthrough designation and a major global installed base of chemiluminescence immunoassay instruments.

Others

  • Quanterix: Quanterix develops the Simoa single-molecule array platform that powers Neurocode's p-Tau 217 assay. Quanterix is both a critical technology partner and a potential competitor through its AccuDx direct testing service. Vertical integration risk: if Quanterix brings biomarker testing in-house, Neurocode becomes a customer rather than a service provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Neurocode social profiles

Digital presence

Neurocode compliance and trust

Trust signal

Compliance2 records

Neurocode financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurocode leadership team

Management profile

Number of profiles

Profiles1 record

Neurocode funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurocode M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurocode

What does Neurocode do?

Neurocode is a CAP/CLIA-certified clinical laboratory that runs specialty diagnostic tests for neurological and neuroimmunological disorders. Its portfolio includes blood- and CSF-based biomarkers for Alzheimer's and neurodegenerative disease (p-Tau 217, GFAP, NfL, Aβ42/40 ratio) and cell-based and radioimmunoprecipitation assays for autoantibody-mediated disorders such as myasthenia gravis, NMOSD, MOGAD, and CIDP. Tests are performed on patient samples (blood or CSF) collected through free collection kits and a national phlebotomy partner network, with results delivered to clinicians via a secure web portal.

Is Neurocode a public or private company?

Neurocode is a private company. It is classified as unknown and is currently operating.

When was Neurocode founded?

Neurocode was founded in 2017. It employs 1 to 10 people.

Where is Neurocode based?

Neurocode is headquartered in Bellingham, United States, in the North America region.

How does Neurocode make money?

One revenue line is on record: clinical Laboratory Diagnostic Testing Services.

Who are Neurocode's main competitors?

Broad incumbents on record are Siemens Healthineers, Quest Diagnostics, Mayo Clinic Laboratories, ARUP Laboratories and LabCorp. Direct peers are C2N Diagnostics, Euroimmun (PerkinElmer), Athena Diagnostics (Quest Diagnostics) and Fujirebio. Quanterix is listed as an others.

Does Neurocode have an API?

No public API is recorded for Neurocode.

What industry is Neurocode in?

Neurocode's product category is Neurological Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeurocode Study Highlights Superior Performance of ALZpath pTau217 Assay in Alzheimer's DiagnosisNeurocode USA Inc published a study in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring comparing the ALZpath pTau217 assay with the Fujirebio assay for Alzheimer's diagnosis, finding that the ALZpath assay demonstrated superior diagnostic accuracy, particularly in early disease stages. The ALZpath assay achieved an area under the curve (AUC) of 0.94, exceeding the 90% accuracy threshold required by the National Institute on Aging and the Alzheimer's Association for AD diagnosis and staging criteria. Neurocode is the only laboratory in the U.S. offering the ALZpath pTau217 assay as a laboratory developed test within a CAP-accredited and CLIA-certified facility, with the assay powered by Quanterix's Simoa® technology.TmcnetGenova Diagnostics Partners with Neurocode to Launch Innovative Alzheimer's AssessmentGenova Diagnostics launched an Alzheimer's Assessment blood test with Neurocode, using the p-Tau217 biomarker for early detection. The test identifies Alzheimer's years before symptoms, offering a less invasive alternative to CSF and imaging. It is now available to healthcare providers.MorningstarGenova Diagnostics Partners with Neurocode to Launch Innovative Alzheimer's AssessmentGenova Diagnostics launched an Alzheimer's Assessment blood test with Neurocode, using the p-Tau217 biomarker to detect Alzheimer's years before symptoms. The test is available to healthcare providers and offers a less invasive alternative to cerebrospinal fluid and imaging tests.PR NewswireGenova Diagnostics Partners with Neurocode to Launch Innovative Alzheimer's AssessmentGenova Diagnostics launched an Alzheimer's Assessment blood test using the p-Tau217 biomarker, developed with Neurocode. The test can identify Alzheimer's years before symptoms appear, offering a less invasive alternative to cerebrospinal fluid and imaging tests. It is now available to healthcare providers.